Kailera Therapeutics, Inc. cotiza a 10.77 USD y tiene una capitalización bursátil de $1.4B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs incl…
| Periodo | 2026-11 | 2026-08 | 2026-05 |
|---|---|---|---|
| Real | — | $-1.09 | $-3.65 |
| Estimado | $-1.01 | $-0.73 | $-0.55 |
| Sorpresa | — | -49.3% | -563.6% |
| Métrica | KLRA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | — | -32.0% | — |
| Current Ratio | 12.01 | 2.84 | +9.17 |
| Debt / Equity | — | 0.28 | — |